Loewenbaum group holds 33% CollPlant (CLGN) stake after warrant deal

Rhea-AI Filing Summary

A group of investors led by the Loewenbaum family reports a large ownership position in CollPlant Biotechnologies Ltd1,764,706 Ordinary Shares plus Series A Warrants for 1,764,706 shares and Series B Warrants for 3,529,412 shares. The deal closed on July 6, 2026. Both warrant series carry a $0.34 exercise price, are exercisable from July 29, 2026, and expire in 2028 and 2031, respectively, subject to a 24.99% Beneficial Ownership Limitation on exercises by The Loewenbaum 1992 Trust.

As of July 29, 2026, CollPlant had 18,908,207 Ordinary Shares outstanding. For ownership calculations, 22,628,318 shares are assumed, including approximately 3,720,111 shares issuable under the warrants within 60 days. On this basis, the Reporting Persons collectively beneficially own 7,473,536 Ordinary Shares, or 33.0% of the company, with The Loewenbaum 1992 Trust accounting for 5,654,817 shares (25.0%). The stake is held for investment purposes, with no specific corporate actions currently planned.

Key Figures

Ordinary Shares purchased: 1,764,706 Ordinary Shares Series A Warrants underlying shares: 1,764,706 Ordinary Shares Series B Warrants underlying shares: 3,529,412 Ordinary Shares +4 more

7 metrics

Ordinary Shares purchased 1,764,706 Ordinary Shares Purchased by The Loewenbaum 1992 Trust under the Securities Purchase Agreement dated June 29, 2026

Series A Warrants underlying shares 1,764,706 Ordinary Shares Shares underlying Series A Warrants at $0.34 exercise price, expiring July 16, 2028

Series B Warrants underlying shares 3,529,412 Ordinary Shares Shares underlying Series B Warrants at $0.34 exercise price, expiring July 16, 2031

Beneficial ownership aggregate 7,473,536 Ordinary Shares Aggregate Ordinary Shares beneficially owned by the Reporting Persons as of July 29, 2026

Beneficial ownership percentage 33.0 % Percentage of total outstanding Ordinary Shares including shares issuable within 60 days

Shares outstanding base 18,908,207 Ordinary Shares Ordinary Shares outstanding as of July 29, 2026, per issuer’s Form F-3

Adjusted shares for ownership calc 22,628,318 Ordinary Shares 18,908,207 outstanding plus 3,720,111 shares from Warrants under the Beneficial Ownership Limitation

Key Terms

Securities Purchase Agreement, Series A Warrants, Series B Warrants, Beneficial Ownership Limitation, +1 more

5 terms

Securities Purchase Agreement regulatory

"entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

Series A Warrants financial

"Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants")"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

Series B Warrants financial

"Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants")"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

Beneficial Ownership Limitation regulatory

"only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99%"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

American Depository Shares financial

"ordinary shares underlying American Depository Shares ("ADSs") held in the Lillian Shaw"

American depository shares are U.S.-listed securities that stand in for a foreign company’s ordinary shares, held by a U.S. bank which issues the ADS so investors can trade the foreign stock in U.S. dollars and on U.S. exchanges. Think of them like a locally wrapped version of a foreign product—easier to buy and sell at home—but they still carry risks from currency differences, foreign rules and potential limits on voting rights, so they affect access, liquidity and investment risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:01 PM Accepted by SEC EDGAR 07/31/2026 - 04:00 PM Learn about SEC filing dates

FAQ

What ownership stake do the Reporting Persons hold in CollPlant Biotechnologies (CLGN)?

The Reporting Persons collectively beneficially own 7,473,536 Ordinary Shares of CollPlant, representing 33.0% of the total outstanding Ordinary Shares, including shares issuable within 60 days from options and warrants under the Beneficial Ownership Limitation framework.

What securities did The Loewenbaum 1992 Trust acquire from CollPlant Biotechnologies (CLGN)?

The Loewenbaum 1992 Trust acquired 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 shares, and Series B Warrants to purchase 3,529,412 shares under a Securities Purchase Agreement dated June 29, 2026, with closing completed on July 6, 2026.

What are the key terms of CollPlant (CLGN) Series A and Series B Warrants held by the Loewenbaum 1992 Trust?

Both Series A and Series B Warrants have a $0.34 exercise price and became exercisable on July 29, 2026. Series A Warrants expire on July 16, 2028, and Series B Warrants expire on July 16, 2031, subject to the 24.99% Beneficial Ownership Limitation.

How many CollPlant (CLGN) shares are used to calculate the Reporting Persons’ ownership percentage?

Ownership percentages are calculated using 22,628,318 Ordinary Shares, based on 18,908,207 shares outstanding as of July 29, 2026, plus approximately 3,720,111 shares representing the maximum issuable upon exercise of the Warrants within 60 days under the Beneficial Ownership Limitation.

What is the Beneficial Ownership Limitation affecting The Loewenbaum 1992 Trust’s CollPlant (CLGN) Warrants?

The Loewenbaum 1992 Trust may exercise its Warrants only up to a 24.99% Beneficial Ownership Limitation. This cap restricts warrant exercises so that, after giving effect to such exercises, the trust’s beneficial ownership does not exceed 24.99% of CollPlant’s outstanding Ordinary Shares.

Who are the main members of the Reporting Persons group in CollPlant Biotechnologies (CLGN)?

The group includes George Walter Loewenbaum, Lilian S. Loewenbaum, Elizabeth S. Loewenbaum, Patrick Chalmers, Reginald J. Hargrove, Nachum Shamir, and entities such as The Loewenbaum 1992 Trust and The Waterproof Partnership, Ltd., all acting as Reporting Persons.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

CollPlant Biotechnologies Ltd

(Name of Issuer)

Ordinary Shares, par value NIS 1.5 per share

(Title of Class of Securities)

19516R107

(CUSIP Number)

Lillian S. Loewenbaum
1000 Westbank Dr, Ste #2A,
Austin, TX, 78746
512-423-5857

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/29/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Loewenbaum Lilian S.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 186,289.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 186,289.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

186,289.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 11: Consists of (a) 25,000 shares of the Issuer's ordinary shares underlying American Depository Shares ("ADSs") held in the Lillian Shaw Loewenbaum Trust, and (b) 161,289 shares of the Issuer's ordinary shares underlying ADSs held by the Reporting Person directly.

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

George Walter Loewenbaum

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,271,056.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,271,056.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,271,056.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.6 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 11: Consists of (a) 65,000 shares of the Issuer's ordinary shares underlying ADSs held by the Walter Loewenbaum Trust, (b) 235,917 ordinary shares underlying ADSs held by the Reporting Person directly, and (c) 970,139 ordinary shares underlying ADSs held by the Reporting Person in an IRA.

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Elizabeth S. Loewenbaum

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 20,688.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 20,688.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

20,688.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

The Loewenbaum 1992 Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,654,817.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,654,817.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,654,817.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

25.0 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

See Item 11: Calculated on the basis assuming exercise of the Warrants up to the Beneficial Ownership Limitation.

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

The Waterproof Partnership, Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 35,500.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 35,500.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

35,500.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

The Loewenbaum Residence Trust FBO Anna Loewenbaum

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 15,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 15,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

15,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

The Elizabeth Scott Loewenbaum 1992 Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

TEXAS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 15,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 15,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

15,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Patrick Chalmers

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,100.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,100.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,100.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Reginald J. Hargrove

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,100.00
8	Shared Voting Power 234,688.00
9	Sole Dispositive Power 6,100.00
10	Shared Dispositive Power 234,688.00

11

Aggregate amount beneficially owned by each reporting person

240,788.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 11: Consists of (a) 20,688 shares of the Issuer's ADSs held by spouse, and (b) 214,000 held by trusts over which the reporting person is a trustee with shared voting and dispositive power.

SCHEDULE 13D

CUSIP Number(s): 19516R107

1

Name of reporting person

Nachum Shamir

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 29,298.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 29,298.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

29,298.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Dual citizen of United States and Israel

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, par value NIS 1.5 per share
(b)	Name of Issuer: CollPlant Biotechnologies Ltd
(c)	Address of Issuer's Principal Executive Offices: 4 Oppenheimer St, Weizmann Science Park, Rehovot, ISRAEL , 7670104.
Item 2.	Identity and Background
(a)	The Waterproof Partnership, Ltd., The Loewenbaum 1992 Trust, The Loewenbaum Residence Trust FBO Anna Loewenbaum and The Elizabeth Scott Loewenbaum 1992 Trust are collectively referred to as the "Reporting Entities" and each as a "Reporting Entity." George Walter Loewenbaum, Elizabeth S. Loewenbaum, Lilian S. Loewenbaum, Patrick Chalmers, Reginald J. Hargrove and Nachum Shamir are referred to herein as the "Individual Filers" and each, an "Individual Filer". The Individual Filers and the Reporting Entities are collectively referred to herein as the "Reporting Persons". The Waterproof Partnership, Ltd., a holding company, is a Texas limited partnership, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as general partners. The Loewenbaum 1992 Trust, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees. The Loewenbaum Residence Trust FBO Anna Loewenbaum, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees. The Elizabeth Scott Loewenbaum 1992 Trust, a holding company, is a Texas trust, with George Walter Loewenbaum and Lilian S. Loewenbaum serving as trustees.
(b)	The address of each Reporting Person, other than Nachum Shamir, is 1000 Westbank Dr, Ste #2A, Austin, TX 78746. George Walter Loewenbaum, Elizabeth S. Loewenbaum, Lilian S. Loewenbaum, Patrick Chalmers and Reginald J. Hargrove are citizens of the United States and their current occupations are individual private investors. Nachum Shamir is a dual citizen of Israel and the United States and his occupation is a private investor. His address is 7900 Escala Dr, Austin TX 78735.
(c)	Refer (b) above
(d)	During the last five years, none of the Reporting Persons nor any general partner or trustee of the Reporting Entities (a) has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors), or (b) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.
(e)	Refer (d) above
(f)	Refer (b) above
Item 3.	Source and Amount of Funds or Other Consideration
	The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein.
Item 4.	Purpose of Transaction
	On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation"). The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price of and other market conditions relating to the Ordinary Shares or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations, and other factors deemed relevant, may form a plan or proposal to take any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, in which case the Reporting Persons will file an amendment to this Schedule 13D. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.
Item 5.	Interest in Securities of the Issuer
(a)	The information concerning the ownership of the Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein. To the best knowledge of the Reporting Persons, as of July 29, 2026, there were 18,908,207 Ordinary Shares outstanding, as set forth in the Form F-3 filed by the Issuer with the SEC on July 9, 2026. The calculations of percentages in this Schedule 13D are based on 22,628,318 Ordinary Shares outstanding as of July 29, 2026, which is based on the 18,908,207 Ordinary Shares as set forth by the Issuer, plus 3,720,111 Ordinary Shares, which is the approximate maximum number of Ordinary Shares obtainable upon exercise of the Warrants up to the Beneficial Ownership Limitation. Collectively, the Reporting Persons beneficially own in the aggregate 7,473,536 Ordinary Shares, representing 33.0% of the total outstanding Ordinary Shares (including approximately 3,720,111 Ordinary Shares that may be issued to the Reporting Persons within 60 days upon the exercise of options and warrants up to the Beneficial Ownership Limitation).
(b)	The information concerning the ownership of Ordinary Shares of the Reporting Persons set forth on the cover pages hereto is expressly incorporated by reference herein.
(c)	Not applicable.
(d)	Except as listed in Item 5(a), to the best knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive, or the power to direct the receipt of dividends from, or the power to direct the receipt of proceeds of the sale of the shares of Common Stock beneficially owned by the Reporting Persons.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The Reporting Persons have entered into a Joint Filing Agreement, dated October 20, 2025, a copy of which is attached hereto as Exhibit 2 to this Schedule 13D and is incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	1. Joint Filing Agreement dated January 28, 2025 (incorporated by reference to Exhibit A to the Schedule 13G/A filed by the Reporting Persons on January 28, 2025). 2. Joint Filing Agreement dated October 20, 2025 (incorporated by reference to Exhibit 2 to the Schedule 13D/A filed by the Reporting Persons on October 20, 2025).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Loewenbaum Lilian S.

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum
Date:	07/31/2026

George Walter Loewenbaum

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum
Date:	07/31/2026

Elizabeth S. Loewenbaum

Signature:	/s/ Elizabeth Loewenbaum
Name/Title:	Elizabeth Loewenbaum
Date:	07/31/2026

The Loewenbaum 1992 Trust

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum/Trustee
Date:	07/31/2026

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum/Trustee
Date:	07/31/2026

The Waterproof Partnership, Ltd.

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum/General Partner
Date:	07/31/2026

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum/General Partner
Date:	07/31/2026

The Loewenbaum Residence Trust FBO Anna Loewenbaum

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum/Trustee
Date:	07/31/2026

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum/Trustee
Date:	07/31/2026

The Elizabeth Scott Loewenbaum 1992 Trust

Signature:	/s/ George Walter Loewenbaum
Name/Title:	George Walter Loewenbaum/Trustee
Date:	07/31/2026

Signature:	/s/ Lillian S. Loewenbaum
Name/Title:	Lillian S. Loewenbaum/Trustee
Date:	07/31/2026

Patrick Chalmers

Signature:	/s/ Patrick Chalmers
Name/Title:	Patrick Chalmers
Date:	07/31/2026

Reginald J. Hargrove

Signature:	/s/ Reginald J. Hargrove
Name/Title:	Reginald J. Hargrove
Date:	07/31/2026

Nachum Shamir

Signature:	/s/ Nachum Shamir
Name/Title:	Nachum Shamir
Date:	07/31/2026